Viridian Therapeutics, Inc. (VRDN)
20.47
+1.44
(+7.57%)
USD |
NASDAQ |
Oct 19, 13:58
Viridian Therapeutics Cash from Operations (Annual) : -276.87M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -276.87M |
| December 31, 2024 | -232.32M |
| December 31, 2023 | -184.17M |
| December 31, 2022 | -93.84M |
| December 31, 2021 | -54.58M |
| December 31, 2020 | -29.78M |
| December 31, 2019 | -36.06M |
| Date | Value |
|---|---|
| December 31, 2018 | -26.84M |
| December 31, 2017 | -28.17M |
| December 31, 2016 | -14.76M |
| December 31, 2015 | -6.898M |
| December 31, 2014 | -2.213M |
| December 31, 2013 | -1.168M |
| December 31, 2012 | -6.225M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.631B |
| TG Therapeutics, Inc. | -24.77M |
| Travere Therapeutics, Inc. | 37.78M |
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |